Leukapheresis Market by Type (Leukapheresis Devices, Leukapheresis Disposables), Application (Research Applications, Therapeutic Applications), End-User - Global Forecast 2024-2030

Leukapheresis Market by Type (Leukapheresis Devices, Leukapheresis Disposables), Application (Research Applications, Therapeutic Applications), End-User - Global Forecast 2024-2030

The Leukapheresis Market size was estimated at USD 56.21 million in 2023 and expected to reach USD 61.62 million in 2024, at a CAGR 9.71% to reach USD 107.58 million by 2030.

The leukapheresis includes the products, devices, procedures, and services related to selectively removing white blood cells (leukocytes) from a patient's or donor's blood. It encompasses different types of leukapheresis procedures, such as autologous leukapheresis and allogeneic leukapheresis, which are applied across various therapeutic areas, including cancer treatment, hematopoietic stem cell transplantation (HSCT), chronic inflammatory diseases management, and immune system regulation. The expanding geriatric population increases the demand for leukapheresis treatments due to their increased susceptibility to age-related diseases. However, the high costs associated with devices and consumables necessary for leukapheresis pose significant barriers for patients and healthcare providers. Nevertheless, ongoing clinical trials exploring novel applications of leukapheresis-derived cells in areas including regenerative medicine present potential opportunities for the leukapheresis market.

Regional Insights

The leukapheresis market is evolving in the Americas with robust healthcare infrastructure, increasing prevalence of leukemia, and adoption of advanced technologies. The European Union (EU) has shown a growing demand for leukapheresis products due to rising incidences of blood disorders. In the EMEA region, increased awareness about leukemia treatment options and improved healthcare infrastructure drive demand for leukapheresis products. The Asia Pacific region represents significant growth in the leukapheresis market due to increased healthcare expenditure, growing awareness of blood disorders, and advancements in healthcare technology. Besides, advancements in leukapheresis devices are anticipated to improve treatment outcomes and encourage their deployment across end-use sectors globally.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Leukapheresis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Increasing application in cancer therapy
Demand for leukapheresis in clinical research
Growth in initiatives for blood donations

Market Restraints

High cost of procedure

Market Opportunities

Focus and investment in R&D activities
Leukapheresis for CAR or Adoptive Cell Therapy

Market Challenges

Potential issues related to leukapheresis including discomfort, redness, and bruising

Market Segmentation Analysis

Type: Increasing use of leukapheresis devices for efficient separation of white blood cells
Application: Rising application of leukapheresis in therapeutics for improved patient outcome
End-User: Proliferating use of leukapheresis devices by blood component providers & blood centers

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Leukapheresis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Leukapheresis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

SCTbio Partners With Cyto-Care To Improve Cell Therapy Cryopreservation

SCTBio and Cyto Care have partnered to enhance cell therapy cryopreservation through leukapheresis. This partnership aims to improve cost-effectiveness, safety, efficiency, and flexibility in cell preservation. The partnership enables both companies to expand their capabilities in research, development, and commercialization of innovative cell therapies.

Akadeum Launches T Cell Activation and Expansion Using Positive Selection and Expands Leukopak Cell Isolation Product Lines

Akadeum Life Sciences has introduced a new service called Leukopak Cell Isolation, which utilizes leukapheresis for cell isolation. This procedure enables the positive selection of specific cells of interest while simultaneously depleting unwanted cells. With Leukopak Cell Isolation, T-cell subsets can be activated and expanded significantly, facilitating therapeutic development.

Fresenius Kabi Launches Single-Needle Option for the Amicus Extracorporeal Photopheresis Protocol

Fresenius Kabi has introduced a single-needle option for the Amicus Extracorporeal Photopheresis protocol used in leukapheresis. This new protocol version offers the same clinical outcomes as its multi-needle predecessor but with added convenience and ease of operation. The design of this new option aims to reduce the risk of air embolism during procedures and promote the cost-effective use of disposables.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Leukapheresis Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Leukapheresis Market, highlighting leading vendors and their innovative profiles. These include Allcells, LLC, Asahi Kasei Corporation, Beijing Zksk Technology Co. Ltd., Bioivt, Caltag Medsystems Limited, Charles River Laboratories International, Inc., Discovery Life Sciences, Fresenius Se & Co. Kgaa, Guangzhou Daji Medical Science and Technology Co. Ltd., Haemonetics Corporation, Intelligent Tissue Group, Lonza Group Ag, Macopharma Sa, Medica Spa., Miltenyi Biotec, Precision for Medicine, Inc., Puriblood Medical Co. Ltd., Stemexpress, LLC, Terumo BCT, and Zenbio, Inc..

Market Segmentation & Coverage

This research report categorizes the Leukapheresis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Leukapheresis Devices
Centrifugal Devices
Membrane Separators
Leukapheresis Disposables
Application
Research Applications
Therapeutic Applications
End-User
Academic & Research Institutes
Blood Component Providers & Blood Centers
Contract Research Organizations
Hospitals & Transfusion Centers
Pharmaceutical & Biotechnology Companies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year